Table of Content

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Rising Global Prevalence of Cancer
4.2.2. Availability of Biomarkers & Biomarker Research for Cancer Diagnosis & Therapy
4.2.3. Recommendations/Guidelines and Programs for Cancer Screening
4.2.4. Growing Number of Clinical Trials for Cancer Drugs
4.2.5. Availability of Advanced Tissue-based Companion Diagnostic Tests
4.2.6. Rising Global Geriatric Population
4.3. Restraints
4.3.1. Product Issues & Recalls
4.4. Opportunities
4.4.1. Rising Focus on Personalized Healthcare
4.4.2. Adoption of Digital Pathology & Automation in Tissue Diagnostics
4.4.3. Emerging Economies
4.5. Challenges
4.5.1. Shortage of Histopathologists
4.5.2. Low Awareness & Lack of Infrastructure in Low- & Middle-income Countries
4.6. The Impact of COVID-19 On the Tissue Diagnostics Market

5. Tissue Diagnostics Market, by Product Type
5.1. Introduction
5.2. Consumables
5.2.1. Kits & Reagents
5.2.2. Antibodies
5.3. Instruments
5.3.1. Slide Staining Systems
5.3.2. Tissue Microarrays
5.3.3. Slide Scanners
5.3.4. Tissue Processors
5.3.5. Other Instruments

6. Tissue Diagnostics Market, by Technique
6.1. Introduction
6.2. Immunohistochemistry (IHC)
6.3. In-Situ Hybridization (ISH)
6.4. Digital Pathology
6.5. H&E and Special Staining
6.6. Molecular Diagnostics
6.7. Other Techniques

7. Tissue Diagnostics Market, by Application
7.1. Introduction
7.2. Breast Cancer
7.3. Lung Cancer
7.4. Colorectal & Gastrointestinal Cancer
7.5. Prostate Cancer
7.6. Lymphoma
7.7. Other Applications

8. Tissue Diagnostics Market, by End User
8.1. Introduction
8.2. Hospitals & Diagnostic Laboratories
8.3. Research Institutes
8.4. Pharmaceutical Companies
8.5. Contract Research Organizations

9. Tissue Diagnostics Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa

10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking

11. Company Profiles
11.1. F. Hoffmann-La Roche Ltd
11.2. Thermo Fisher Scientific Inc.
11.3. Abbott Laboratories
11.4. Danaher Corporation
11.5. QIAGEN N.V.
11.6. Becton, Dickinson and Company
11.7. Abcam Plc
11.8. Agilent Technologies, Inc.
11.9. Merck KGaA
11.10. Sakura Finetek Japan Co., Ltd.
11.11. Cell Signaling Technology, Inc.
11.12. Bio-Genex Laboratories
11.13. Bio SB, Inc
11.14. 3DHISTECH
11.15. Hologic, Inc.

12. Appendix
12.1. Questionnaire
12.2. Available Customization



List of Figures

List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Tissue Diagnostics Market Size, by Product Type, 2022–2029 (USD Million)
Figure 8 Global Tissue Diagnostics Market Size, by Technique, 2022–2029 (USD Million)
Figure 9 Global Tissue Diagnostics Market Size, by Application, 2022–2029 (USD Million)
Figure 10 Global Tissue Diagnostics Market Size, by End User, 2022–2029 (USD Million)
Figure 11 Global Tissue Diagnostics Market, by Geography
Figure 12 Market Dynamics
Figure 13 Global Cancer Prevalence, by Type (2020)
Figure 14 Percentage of Oncology Drugs Among All Drugs in the R&D Pipeline (2015–2021)
Figure 15 Population Aged 65 Years Or Over, by Region, 2020 VS. 2030 (In Million)
Figure 16 Global Tissue Diagnostics Market Size, by Product, 2022 Vs 2029 (USD Million)
Figure 17 Global Tissue Diagnostics Market Size, by Technique, 2022 Vs 2029 (USD Million)
Figure 18 Global Tissue Diagnostics Market Size, by Application, 2022 Vs 2029 (USD Million)
Figure 19 Global Tissue Diagnostics Market, by End User, 2022 Vs 2029 (USD Million)
Figure 20 Global Tissue Diagnostics Market Size, by Region, 2022 VS 2029 (USD Million)
Figure 21 North America: Tissue Diagnostics Market Snapshot
Figure 22 U.S.: Number of New Cancer Cases (2010–2030)
Figure 23 Canada: Number of Breast Cancer Cases (2014–2030)
Figure 24 Europe: Tissue Diagnostics Market Snapshot
Figure 25 Italy: Number of Breast Cancer Cases (2020–2040)
Figure 26 Asia-Pacific: Tissue Diagnostics Market Snapshot
Figure 27 Japan: Estimated Number of People Over 65 Years of Age, 2010–2050
Figure 28 Japan: New Breast Cancer Cases 2012–2020
Figure 29 India: New Breast Cancer Cases 2012–2030
Figure 30 Mexico: Per Capita Healthcare Spending, 2017–2020 (USD)
Figure 31 Latin America: Age Standardised Cancer Incidence Rates (Asrs), Per 100,000 Population, 2020
Figure 32 Latin America: Estimated Number of Cancer Cases, 2020
Figure 33 Key Growth Strategies Adopted by Leading Players (2019–2022)
Figure 34 Tissue Diagnostics Market: Competitive Benchmarking
Figure 35 F. HOFFMAN-LA ROCHE LTD.: FINANCIAL OVERVIEW (2021)
Figure 36 Thermo Fisher Scientific Inc.: FINANCIAL OVERVIEW (2021)
Figure 37 Abbott Laboratories: FINANCIAL OVERVIEW (2021)
Figure 38 Danaher Corporation: FINANCIAL OVERVIEW (2021)
Figure 39 QIAGEN N.V.: FINANCIAL OVERVIEW (2021)
Figure 40 Becton, Dickinson And Company: FINANCIAL OVERVIEW (2021)
Figure 41 Abcam Plc: Financial Overview (2021)
Figure 42 Agilent Technologies, Inc.: Financial Overview (2021)
Figure 43 Merck KGaA: Financial Overview (2021)
Figure 44 Hologic Inc.: FINANCIAL OVERVIEW (2021)